Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Humana and Boehringer Ingelheim Report New Findings on COPD Medication Adherence

XTALKS VITALS NEWS

Inhaler

There is no cure for COPD, however currently-available treatments aim to reduce the frequency and severity of symptoms, which include coughing, breathlessness and tightness in the chest.

Share this!

January 10, 2017 | by Sarah Hand, M.Sc.

Healthcare insurance company, Humana, and global pharmaceutical company, Boehringer Ingelheim, have found an association between medication adherence to chronic obstructive pulmonary disease (COPD) treatments and other chronic disease drugs. The findings were published in the International Journal of COPD.

COPD is a respiratory disease which progressively worsens over time. There is no cure for COPD, however currently-available treatments aim to reduce the frequency and severity of symptoms, which include coughing, breathlessness and tightness in the chest.

“Because people living with COPD are frequently diagnosed with another chronic disease, such as cardiovascular disease or diabetes, we designed this new study to explore the relationship between adherence to daily medicines for these other diseases and adherence to daily maintenance medicines for COPD,” said study co-author, Phil Schwab with Humana's Comprehensive Health Insights. “The study results showed patients who are likely to be non-adherent to other medicines are also likely to be non-adherent to their COPD medicines.”



According to the study authors, this finding suggests that non-adherence to medications for chronic conditions like COPD, could be caused by a number of factors that affect a person’s ability and willingness to take their medication as prescribed. These factors could be behavioural in nature – such as forgetfulness – or they could relate to a patient’s socioeconomic situation – including low income, low health literacy or lack of coordinated healthcare.

“These findings are important, because they help guide physicians on how best to support COPD patients with historically low adherence in taking their medications so they can achieve optimal health outcomes,” said Dr. Andrew Renda, Bold Goal Director for Humana. “Rather than focus on the number and type of comorbidities with COPD, holistic adherence improvement efforts should address access, affordability, and most importantly, education on how these medications improve symptoms and quality of life while reducing the risk of exacerbations.”

Over 15 million Americans have been diagnosed with COPD, according to the Centers for Disease Control and Prevention. COPD, along with other lower respiratory diseases, represent the third leading cause of death in the US.


Keywords: COPD, Medication Adherence, Chronic Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.